855
Participants
Start Date
September 19, 2016
Primary Completion Date
August 2, 2017
Study Completion Date
August 2, 2017
Tazarotene Cream 0.05%
Tazarotene Cream 0.05% to cover only the lesions with a thin film.
TAZORAC® (tazarotene) Cream 0.05%
TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
Placebo
Placebo (vehicle of the test product) to cover only the lesions with a thin film.
Fougera Investigational Site, Upper Saint Clair
Fougera Investigational Site, Hazleton
Fougera Investigational Site, High Point
Fougera Investigational Site, Macon
Fougera Investigational Site, Miami
Fougera Investigational Site, Hialeah
Fougera Investigational Site, Miramar
Fougera Investigational Site, Coral Gables
Fougera Investigational Site, Miami
Fougera Investigational Site, Miami Gardens
Fougera Investigational Site, Sweetwater
Fougera Investigational Site, Miami
Fougera Investigational Site, West Palm Beach
Fougera Investigational Site, Brandon
Fougera Investigational Site, Tampa
Fougera Investigational Site, Louisville
Fougera Investigational Site, Plainfield
Fougera Investigational Site, New Albany
Fougera Investigational Site, Arlington Heights
Fougera Investigational Site, Lake Charles
Fougera Investigational Site, Hot Springs
Fougera Investigational Site, San Antonio
Fougera Investigational Site, Phoenix
Fougera Investigational Site, Henderson
Fougera Investigational Site, North Hollywood
Fougera Investigational Site, Saint Joseph
Fougera Investigational Site, San Diego
Fougera Investigational Site, Anaheim
Fougera Investigational Site, San Ramon
Fougera Investigational Site, Salem
Lead Sponsor
Fougera Pharmaceuticals Inc.
INDUSTRY